



## SARS-CoV-2 in pleural fluid in a kidney transplant patient

This is the peer reviewed version of the following article:

*Original:*

Bennett, D., Franchi, F., De Vita, E., Mazzei, M.A., Volterrani, L., Disanto, M.G., et al. (2021). SARS-CoV-2 in pleural fluid in a kidney transplant patient. POSTGRADUATE MEDICINE, 133(5), 540-543 [10.1080/00325481.2020.1838817].

*Availability:*

This version is available <http://hdl.handle.net/11365/1118094> since 2020-10-24T16:44:28Z

*Published:*

DOI:10.1080/00325481.2020.1838817

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)



## SARS-CoV-2 in pleural fluid in a kidney transplant patient

David Bennett , Federico Franchi , Elda De Vita , Maria Antonietta Mazzei , Luca Volterrani , Maria Giulia Disanto , Guido Garosi , Andrea Guarnieri , Maria Grazia Cusi , Elena Bargagli , Sabino Scolletta , Serafina Valente , Roberto Gusinu & Bruno Frediani

To cite this article: David Bennett , Federico Franchi , Elda De Vita , Maria Antonietta Mazzei , Luca Volterrani , Maria Giulia Disanto , Guido Garosi , Andrea Guarnieri , Maria Grazia Cusi , Elena Bargagli , Sabino Scolletta , Serafina Valente , Roberto Gusinu & Bruno Frediani (2020): SARS-CoV-2 in pleural fluid in a kidney transplant patient, Postgraduate Medicine, DOI: [10.1080/00325481.2020.1838817](https://doi.org/10.1080/00325481.2020.1838817)

To link to this article: <https://doi.org/10.1080/00325481.2020.1838817>



Accepted author version posted online: 18 Oct 2020.



Submit your article to this journal [↗](#)



Article views: 71



View related articles [↗](#)



View Crossmark data [↗](#)

**Publisher:** Taylor & Francis & Informa UK Limited, trading as Taylor & Francis Group

**Journal:** *Postgraduate Medicine*

**DOI:** 10.1080/00325481.2020.1838817

**Title:** SARS-CoV-2 in pleural fluid in a kidney transplant patient

Running title: SARS-CoV-2 in pleural fluid

David Bennett MD, PhD 1, Federico Franchi MD 2,3, Elda De Vita MD 1, Maria Antonietta Mazzei MD 3,4, Luca Volterrani MD 3,4, Maria Giulia Disanto MD 5, Guido Garosi MD 6, Andrea Guarnieri MD 6, Maria Grazia Cusi MD 7, Elena Bargagli MD, PhD 1,3, Sabino Scolletta MD 2,3, Serafina Valente MD 8, Roberto Gusinu MD 9, Bruno Frediani MD 10,3

1 Respiratory Diseases Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

2 DEA and Transplant Anesthesia and Resuscitation Unit, Department of Emergency-Urgency and Transplantation, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

3 Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy

4 Diagnostic Imaging Unit, Department of Radiological Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

5 Pathology Unit, Department of Oncology, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

6 Nephrology, dialysis and transplantation Unit, Department of Emergency-Urgency and Transplantation, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

7 Microbiology and Virology Unit, Department of Innovation, Experimentation and Clinical Research, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

8 Clinical and Surgical Cardiology Unit, Cardio-Thoracic and Vascular Department, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

9 Health Service Management Board, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

10 Rheumatology Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

Corresponding author:

David Bennett, MD, PhD

Respiratory Diseases Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

Viale Bracci, 16 – 53100 Siena, Italy

Tel: +390577586710; Fax: +390577280744

Email: [david.btt@gmail.com](mailto:david.btt@gmail.com)

Social Media:

Facebook: david.bennett.31

Linkedin: <https://www.linkedin.com/in/david-bennett-73a97267/>

Researchgate: [https://www.researchgate.net/profile/David\\_Bennett25](https://www.researchgate.net/profile/David_Bennett25)

ORCID iDs:

David Bennett 0000-0001-5354-152X

Federico Franchi 0000-0002-4448-1892

Elda De Vita 0000-0001-7403-6389

Maria Antonietta Mazzei 0000-0001-6778-6894

Luca Volterrani NOT AVAILABLE

Maria Giulia Disanto NOT AVAILABLE

Guido Garosi NOT AVAILABLE

Andrea Guarnieri NOT AVAILABLE

Maria Grazia Cusi 0000-0001-8869-8164

Elena Bargagli 0000-0002-8351-3703

Sabino Scolletta 0000-0003-3709-2052

Serafina Valente 0000-0002-0808-3512

Roberto Gusinu NOT AVAILABLE

Bruno Frediani NOT AVAILABLE

ACCEPTED MANUSCRIPT

## SARS-CoV-2 in pleural fluid in a kidney transplant patient

### SARS-CoV-2 in pleural fluid

David Bennett<sup>1</sup>, Federico Franchi<sup>2,3</sup>, Elda De Vita<sup>1</sup>, Maria Antonietta Mazzei<sup>3,4</sup>, Luca Volterrani<sup>3,4</sup>, Maria Giulia Disanto<sup>5</sup>, Guido Garosi<sup>6</sup>, Andrea Guarnieri<sup>6</sup>, Maria Grazia Cusi<sup>7</sup>, Elena Bargagli<sup>1,3</sup>, Sabino Scolletta<sup>2,3</sup>, Serafina Valente<sup>8</sup>, Roberto Gusinu<sup>9</sup>, Bruno Frediani<sup>10,3</sup>

<sup>1</sup> Respiratory Diseases Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>2</sup> DEA and Transplant Anesthesia and Resuscitation Unit, Department of Emergency-Urgency and Transplantation, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>3</sup> Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy

<sup>4</sup> Diagnostic Imaging Unit, Department of Radiological Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>5</sup> Pathology Unit, Department of Oncology, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>6</sup> Nephrology, dialysis and transplantation Unit, Department of Emergency-Urgency and Transplantation, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>7</sup> Microbiology and Virology Unit, Department of Innovation, Experimentation and Clinical Research, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>8</sup> Clinical and Surgical Cardiology Unit, Cardio-Thoracic and Vascular Department, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>9</sup> Health Service Management Board, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

<sup>10</sup> Rheumatology Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Siena, Italy

### Corresponding author

David Bennett

Respiratory Diseases Unit, Department of Medical Sciences, University Hospital of Siena

(Azienda Ospedaliera Universitaria Senese, AOUS),

Siena, Italy

Viale Bracci, 16 – 53100 Siena,

Italy

david.btt@gmail.com

**ORCID IDs**

David Bennett 0000-0001-5354-152X

Federico Franchi 0000-0002-4448-1892

Elda De Vita 0000-0001-7403-6389

Maria Antonietta Mazzei 0000-0001-6778-6894

Maria Grazia Cusi 0000-0001-8869-8164

Elena Bargagli 0000-0002-8351-3703

Sabino Scolletta 0000-0003-3709-2052

Serafina Valente 0000-0002-0808-3512

ACCEPTED MANUSCRIPT

## Abstract

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread all over the globe from China. Pleural involvement is not common; around 5-10% of patients can develop pleural effusion and little is known about the involvement of pleural structures in this new infection.

A 61-year-old male kidney transplant patient with a history of multiple biopsy-confirmed acute rejections and chronic allograft rejection was admitted to our COVID-19 Unit with dry cough, exertional dyspnea, oliguria and abdominal distension. Lung ultrasound imaging, chest X-ray and CT scan showed left pleural effusion and atelectasis of the neighboring lung parenchyma. RT-PCR was positive for SARS-CoV-2 in the pleural fluid and cytology showed mesothelial cells with large and multiple nuclei, consistent with a cytopathic effect of the virus.

This is one of few reports describing detection of SARS-CoV-2 in the pleural fluid and to the best of our knowledge, is the first to document the simultaneous presence of a direct cytopathic effect of the virus on mesothelial cells in a kidney transplant patient with COVID-19 pneumonia. The pleura proved to be a site of viral replication where signs of a direct pathological effect of the virus on cells can be observed, as we report here. RT-PCR for SARS-CoV-2 should be part of routine examination of pleural effusion even in patients with mild respiratory symptoms or with comorbidities that seem to explain the cause of effusion.

**Keywords:** COVID-19, SARS-CoV-2, pleural fluid, transplant

ACCEPTED MANUSCRIPT



## Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection spread rapidly around the world from China. Common symptoms of Coronavirus disease 2019 (COVID-19) at presentation include fever, dyspnoea, dry cough, fatigue and diarrhoea (1). Nasal congestion and anosmia have also been reported (1, 2). Interstitial pneumonia is the major clinical manifestation and around 10% of patients develop severe acute respiratory distress syndrome (ARDS) (3, 4). Pleural involvement is not common; around 5-10% of patients can develop pleural effusion but little is known about involvement of pleural structures in this new infection (5).

This is one of few reports describing detection of SARS-CoV-2 in pleural fluid, and to the best of our knowledge, it is the first to document the simultaneous presence of a direct cytopathic effect of the virus on mesothelial cells in a kidney transplant patient with COVID-19 pneumonia.

## Case report

A 61-year-old male kidney transplant patient with a history of multiple biopsy-confirmed acute rejections and chronic allograft rejection was admitted to our COVID-19 Unit on 9th April 2020. Renal function was severely reduced and serum creatinine measured 3 weeks before admission was 7.59 mg/dl (glomerular filtration rate 16 ml/min), although he was not yet on dialysis. His maintenance immunosuppressant therapy consisted of prednisone, tacrolimus and mycophenolate mofetil.

On admission, the patient presented with mild respiratory symptoms, oliguria and abdominal distension. He reported a dry cough and exertional dyspnea in the previous week and a nasopharyngeal swab was positive for SARS-CoV-2. Since serum creatinine was 11.1 mg/dl, hemodialysis was immediately begun. He also showed severe anemia and leucopenia while C-reactive protein was 4.00 mg/dl (see Table 1 for complete lab data). Chest auscultation revealed wheezing, basal right crackles, basal left reduction of physiological vesicular murmur and dullness to percussion. Lung ultrasound imaging indicated an interstitial syndrome with bilateral diffuse multiple B lines and left basal pleural effusion. Chest X-ray showed left pleural effusion and a CT scan confirmed the left pleural effusion and atelectasis of the neighboring lung parenchyma with no signs of viral parenchymal involvement (Figure 1a).

The laboratory characteristics of the fluid were compatible with transudative effusion (Table 2). Reverse transcriptase-polymerase chain reaction (RT-PCR) was positive for SARS-CoV-2 and cytology showed mesothelial cells with large multiple nuclei, consistent with a cytopathic effect of the virus (Figure 1b); microbiology was negative.

The patient was treated with methylprednisolone 1.5 mg/kg/day for 5 days while the other immunosuppressants were suspended. Respiratory condition improved rapidly and the nasopharyngeal swab for SARS-CoV-2 became negative 8 days after admission. Unfortunately, renal function did not improve and long-term hemodialysis was begun. During hospitalization, the patient also developed a perforated diverticulum and left hemicolectomy was necessary. Despite the difficulties encountered during hospital stay, the patient recovered completely and was discharged 28 days after admission.

## Discussion

SARS-CoV-2 infection may present with different symptoms that express direct or indirect involvement of various organs and systems (5). In most patients, imaging of the lung shows ground glass opacities and crazy paving pattern in the early phases, and later larger consolidations in the basal or dependent lung regions, readily visible by CT (6). Due to its safety, repeatability, absence of radiation, low cost and point of care use, ultrasound imaging of the lungs has shown good clinical value in COVID-19 patients (7). Despite the high sensitivity of these techniques, pleural effusion has only occasionally been reported in COVID-19 (5). In our experience, the incidence of pleural effusion in hospitalized COVID-19 patients is 7.5%; in most cases it was mild, not requiring drainage.

Mei et al. recently published a case report of a COVID-19 patient whose pleural fluid RT-PCR was positive for SARS-CoV-2 (8). The present report is the first concerning pleural effusion in a kidney transplant patient with COVID-19. In our case RT-PCR of pleural fluid was positive for SARS-CoV-2, and we also documented mesothelial cells with large multiple nuclei, consistent with a cytopathic effect of the virus. Unfortunately, we were unable to perform electron microscopy.

Dysregulated and/or exaggerated cytokine and chemokine responses in SARS-CoV-2 infection have been reported in many studies. Cytokine release syndrome is a systemic inflammatory response, that can be triggered by infection, certain drugs and other factors. It has been demonstrated in COVID-19 patients (9). *In vitro* experiments show that delayed release of cytokines and chemokines occurs in respiratory epithelial cells, dendritic cells and macrophages in the early stage of SARS-CoV-2 infection, and that the cells secrete low levels of interferon antiviral factors and high levels of proinflammatory cytokines (interleukins IL-1 $\beta$ , IL-6, and tumor necrosis factor) and chemokines (10). No specific antiviral therapy for SARS-CoV-2 infection has yet been found, although most reports suggest that immunomodulation therapy can play a positive role. Blockade of IL-6 and IL-1 has shown promising results and high doses of steroids prove to reduce mortality, moderating cytokine release (9, 11).

The angiotensin converting enzyme 2 (ACE2) receptor proves to play a crucial role in viral entry into cells and its reduced transmembrane expression is associated with increased risk of ARDS in infected subjects (12). Drugs interfering with ACE2 receptor show promising positive effects, making the receptor a major focus in the search for new therapies (13).

In solid organ transplant recipients, such as our patient, the risk of pneumonia and development of ARDS is expected to be higher, although a number of reports have indicated a similar incidence to that of the general population (14, 15). The hypothesis that post-transplant immunosuppression can somehow protect patients against the hyperinflammatory syndrome resulting from the cytokine storm induced by SARS-CoV-2 is intriguing and needs further confirmation (9, 16). In the present case, despite the setbacks our patient had to face (severe kidney failure and intestinal perforation requiring dialysis and surgery, respectively), the outcome was positive and the patient was eventually discharged.

Diagnostic and therapeutic procedures, such as thoracentesis, must only be performed in COVID-19 patients if there are strict clinical indications. All safety criteria for operators performing collection and

analysis of samples must comply with international standards. In our case, pleural fluid was drawn at the patient's bedside in the COVID-19 isolation ward. The pleural fluid samples were treated according to current national and international regulations. All diagnostic laboratories in our hospital operate at biosecurity levels 2, 3 and 4, and are able to handle biological samples potentially infected with SARS-CoV 2 (17).

## **Conclusions**

Although pleural involvement is not common in COVID-19, patients should be checked for the presence of effusion. Signs of a direct pathological effect on pleural cells can even be observed in cases with mild/moderate pneumonia, as we report in this case, suggesting that the pulmonary and pleural compartments may behave distinctly and that participation of the pleura is not always a result of pulmonary spread. However, we do not have reliable data to support this hypothesis, verification of which will require further studies. RT-PCR for SARS-CoV-2 should be part of routine examination of pleural effusion, even in patients with mild respiratory symptoms or with comorbidities that seem to explain the cause of effusion. How to treat SARS-CoV-2 infection is still debated. Immune modulation has shown promising results and several trials are underway (11). Solid organ transplant patients offer a unique *in vivo* model of biological responses to this new virus and can be useful to help understand response to therapy. Pleural drainage should nevertheless be an aspect of non-pharmacological therapy in selected COVID-19 patients to improve respiratory dynamics and prognosis.

## **Transparency**

### **Declaration of funding**

There was no funding received for this article.

### **Declaration of financial/other relationships**

The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.

The authors have no conflicts of interest to declare.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

## **Authors contribution**

DB performed the literature search, data collection, data analysis and interpretation and wrote the manuscript. FF, EDV, MAM, LV, MGD, GG, AG, MGC, EB, SS, SV, RG and BF performed data analysis and interpretation. All authors contributed equally to clinical management of the patient during his hospital stay. All authors are guarantors of the paper, taking responsibility for the integrity of the work as a whole.

All authors read and approved the final version of the manuscript.

## References

1. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol*. 2020 Jul;92(7):797-806.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020 Feb 15;395(10223):507-513.
3. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med*. 2020 May 15;201(10):1299-1300.
4. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet*. 2020 Apr 11;395(10231):1225-1228.
5. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. *Invest Radiol*. 2020 Jun;55(6):327-331.
6. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology*. 2020 Jun;295(3):715-721.
7. Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. *Anaesthesia*. 2020 Apr 10:10.1111/anae.15082.
8. Mei F, Bonifazi M, Menzo S, Di Marco Bernardino A, Sediari M, Paolini L, Re A, Gonnelli F, Grilli M, Vennarucci GS, Latini MA, Zuccatosta L, Gasparini S. First detection of SARS-CoV-2 by real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay in pleural fluid, CHEST (2020), doi: <https://doi.org/10.1016/j.chest.2020.05.583>
9. Capecchi PL, Lazzarini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B. Antirheumatic agents in covid-19: is IL-6 the right target? *Ann Rheum Dis*. 2020 Apr 16:annrheumdis-2020-217523.
10. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect*. 2020 Jun;80(6):607-613.
11. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. *Nature*. 2020 Jun 16
12. Alfano G, Guaraldi G, Fontana F, Ferrari A, Magistrini R, Mussini C, Cappelli G; for the Modena Covid-19 Working Group (MoCo19). The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection. *Blood Purif*. 2020 Apr 28:1-5
13. Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, Neuhold S, Haider D, Stiasny K, Bergthaler A, Puchhammer-Stoeckl E, Mirazimi A, Montserrat A, Zhang H, Slutsky AS, Penninger JM. Human recombinant soluble ACE2 in severe COVID-19. *Lancet Respir Med* 2020 Published Online September 24, 2020 [https://doi.org/10.1016/S2213-2600\(20\)30418-5](https://doi.org/10.1016/S2213-2600(20)30418-5)
14. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant*. 2020 Apr 16.

15. Bennett D, De Vita E, Ventura V, Bernazzali S, Fossi A, Paladini P, Luzzi L, Maccherini M, Valente S, Bargagli E, Frediani B, Sestini P. Impact of SARS-CoV-2 outbreak on heart and lung transplant: A patient-perspective survey. *Transpl Infect Dis.* 2020 Aug 2:e13428.
16. Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. *Ann Rheum Dis.* 2020 May 15:annrheumdis-2020-217681.
17. National Research Council (US) Committee on Prudent Practices in the Laboratory. Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: Updated Version. Washington (DC): National Academies Press (US); 2011. 4, Evaluating Hazards and Assessing Risks in the Laboratory.

## CAPTIONS

**Figure 1:** A: Chest CT after intravenous administration of only 60 ml of contrast medium. Virtual monoenergetic reconstruction (55 KeV) of dual energy CT data shows pleural effusion and atelectasis of the neighbouring lung parenchyma and excludes active foci of bleeding. B: Microvacuolated macrophages and scattered mesothelial cells with enlarged multiple nuclei suggesting viral infection.

**Table 1:** Lab findings on admission to hospital

**Table 2:** Features of pleural fluid

**Table 1**

C-reactive protein	4.00 mg/dL
Lactate dehydrogenase	262 IU/L
D-dimer	478 ug/L
Ferritin	925 ng/mL
White blood cells	$2.63 \times 10^3/\text{mmc}$
• Neutrophils	67.8%
• Lymphocytes	20.5%
• Monocytes	9.1%
• Eosinophils	1.5%
• Basophils	1.15
Red blood cells	$2.19 \times 10^6/\text{mmc}$
Hemoglobin	6.2 g/dL
Hematocrit	19.4%
Mean Corpuscular Volume	88.6 fL
Mean Corpuscular Hemoglobin	28.3 pg
Mean Corpuscular Hemoglobin Concentration	32.0 g/dL
Red blood cell Distribution Width	16.8%
Platelets	$148 \times 10^3/\text{mmc}$
Glucose	71 mg/dL
Creatinine	11.1 mg/dL
Blood Urea Nitrogen	212 mg/dL
Cholesterol	161 mg/dL
Total proteins	4.2 g/dL
Albumin	2.4 g/dL
Bilirubin	0.3 mg/dL
Glutamic oxaloacetic transaminase	10 IU/L
Glutamate-pyruvate transaminase	8 IU/L

**Table 2**

Appearance	clear
Colour	yellow
Total protein	2 g/dL
Lactate dehydrogenase	79 U/L
White cell count	25/mcl (80% mononuclear cells)

ACCEPTED MANUSCRIPT




Fig 1

ACCEPTED MANUSCRIPT